Charles River Magellan Collaboration Backs Zelestrocel Osteoarthritis Therapy With cGMP NGS Viral Safety Testing
Charles River Laboratories and Magellan Stem Cells announced a collaboration on Oct. 13, 2026, bringing cGMP next-generation sequencing viral safety testing to Zelestrocel, Magellan’s off-the-shelf osteoarthritis stem cell therapy candidate.
